<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 18:54:01 -0700</creation_date>
  <update_date>2013-01-15 18:54:01 -0700</update_date>
  <accession>HMDBP01189</accession>
  <secondary_accessions>
    <accession>6485</accession>
  </secondary_accessions>
  <protein_type>Enzyme</protein_type>
  <synonyms>
    <synonym>CD135 antigen</synonym>
    <synonym>FLT-3</synonym>
    <synonym>Fms-like tyrosine kinase 3</synonym>
    <synonym>STK-1</synonym>
    <synonym>Stem cell tyrosine kinase 1</synonym>
    <synonym>Tyrosine-protein kinase receptor FLT3</synonym>
  </synonyms>
  <gene_name>FLT3</gene_name>
  <general_function>Involved in protein kinase activity</general_function>
  <specific_function>Receptor for the FL cytokine. Has a tyrosine-protein kinase activity</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00538</accession>
      <name>Adenosine triphosphate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01341</accession>
      <name>ADP</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14542</accession>
      <name>Sorafenib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15397</accession>
      <name>Sunitinib</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>protein binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>protein tyrosine kinase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transmembrane receptor protein tyrosine kinase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>nucleoside binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>purine nucleoside binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>adenyl nucleotide binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>adenyl ribonucleotide binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>atp binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transferase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transferase activity, transferring phosphorus-containing groups</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>kinase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>protein kinase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signaling</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cell surface receptor linked signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>enzyme linked receptor protein signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>transmembrane receptor protein tyrosine kinase signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>phosphorus metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>phosphate metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>phosphorylation</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>protein amino acid phosphorylation</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intrinsic to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to membrane</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Membrane</subcellular_location>
    <subcellular_location>Single-pass type I membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:1</chromosome_location>
    <locus>13q12</locus>
    <gene_sequence>&gt;2982 bp
ATGCCGGCGTTGGCGCGCGACGGCGGCCAGCTGCCGCTGCTCGTTGTTTTTTCTGCAATG
ATATTTGGGACTATTACAAATCAAGATCTGCCTGTGATCAAGTGTGTTTTAATCAATCAT
AAGAACAATGATTCATCAGTGGGGAAGTCATCATCATATCCCATGGTATCAGAATCCCCG
GAAGACCTCGGGTGTGCGTTGAGACCCCAGAGCTCAGGGACAGTGTACGAAGCTGCCGCT
GTGGAAGTGGATGTATCTGCTTCCATCACACTGCAAGTGCTGGTCGATGCCCCAGGGAAC
ATTTCCTGTCTCTGGGTCTTTAAGCACAGCTCCCTGAATTGCCAGCCACATTTTGATTTA
CAAAACAGAGGAGTTGTTTCCATGGTCATTTTGAAAATGACAGAAACCCAAGCTGGAGAA
TACCTACTTTTTATTCAGAGTGAAGCTACCAATTACACAATATTGTTTACAGTGAGTATA
AGAAATACCCTGCTTTACACATTAAGAAGACCTTACTTTAGAAAAATGGAAAACCAGGAC
GCCCTGGTCTGCATATCTGAGAGCGTTCCAGAGCCGATCGTGGAATGGGTGCTTTGCGAT
TCACAGGGGGAAAGCTGTAAAGAAGAAAGTCCAGCTGTTGTTAAAAAGGAGGAAAAAGTG
CTTCATGAATTATTTGGGATGGACATAAGGTGCTGTGCCAGAAATGAACTGGGCAGGGAA
TGCACCAGGCTGTTCACAATAGATCTAAATCAAACTCCTCAGACCACATTGCCACAATTA
TTTCTTAAAGTAGGGGAACCCTTATGGATAAGGTGCAAAGCTGTTCATGTGAACCATGGA
TTCGGGCTCACCTGGGAATTAGAAAACAAAGCACTCGAGGAGGGCAACTACTTTGAGATG
AGTACCTATTCAACAAACAGAACTATGATACGGATTCTGTTTGCTTTTGTATCATCAGTG
GCAAGAAACGACACCGGATACTACACTTGTTCCTCTTCAAAGCATCCCAGTCAATCAGCT
TTGGTTACCATCGTAGAAAAGGGATTTATAAATGCTACCAATTCAAGTGAAGATTATGAA
ATTGACCAATATGAAGAGTTTTGTTTTTCTGTCAGGTTTAAAGCCTACCCACAAATCAGA
TGTACGTGGACCTTCTCTCGAAAATCATTTCCTTGTGAGCAAAAGGGTCTTGATAACGGA
TACAGCATATCCAAGTTTTGCAATCATAAGCACCAGCCAGGAGAATATATATTCCATGCA
GAAAATGATGATGCCCAATTTACCAAAATGTTCACGCTGAATATAAGAAGGAAACCTCAA
GTGCTCGCAGAAGCATCGGCAAGTCAGGCGTCCTGTTTCTCGGATGGATACCCATTACCA
TCTTGGACCTGGAAGAAGTGTTCAGACAAGTCTCCCAACTGCACAGAAGAGATCACAGAA
GGAGTCTGGAATAGAAAGGCTAACAGAAAAGTGTTTGGACAGTGGGTGTCGAGCAGTACT
CTAAACATGAGTGAAGCCATAAAAGGGTTCCTGGTCAAGTGCTGTGCATACAATTCCCTT
GGCACATCTTGTGAGACGATCCTTTTAAACTCTCCAGGCCCCTTCCCTTTCATCCAAGAC
AACATCTCATTCTATGCAACAATTGGTGTTTGTCTCCTCTTCATTGTCGTTTTAACCCTG
CTAATTTGTCACAAGTACAAAAAGCAATTTAGGTATGAAAGCCAGCTACAGATGGTACAG
GTGACCGGCTCCTCAGATAATGAGTACTTCTACGTTGATTTCAGAGAATATGAATATGAT
CTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTTTGGGAAGGTACTAGGATCAGGTGCT
TTTGGAAAAGTGATGAACGCAACAGCTTATGGAATTAGCAAAACAGGAGTCTCAATCCAG
GTTGCCGTCAAAATGCTGAAAGAAAAAGCAGACAGCTCTGAAAGAGAGGCACTCATGTCA
GAACTCAAGATGATGACCCAGCTGGGAAGCCACGAGAATATTGTGAACCTGCTGGGGGCG
TGCACACTGTCAGGACCAATTTACTTGATTTTTGAATACTGTTGCTATGGTGATCTTCTC
AACTATCTAAGAAGTAAAAGAGAAAAATTTCACAGGACTTGGACAGAGATTTTCAAGGAA
CACAATTTCAGTTTTTACCCCACTTTCCAATCACATCCAAATTCCAGCATGCCTGGTTCA
AGAGAAGTTCAGATACACCCGGACTCGGATCAAATCTCAGGGCTTCATGGGAATTCATTT
CACTCTGAAGATGAAATTGAATATGAAAACCAAAAAAGGCTGGAAGAAGAGGAGGACTTG
AATGTGCTTACATTTGAAGATCTTCTTTGCTTTGCATATCAAGTTGCCAAAGGAATGGAA
TTTCTGGAATTTAAGTCGTGTGTTCACAGAGACCTGGCCGCCAGGAACGTGCTTGTCACC
CACGGGAAAGTGGTGAAGATATGTGACTTTGGATTGGCTCGAGATATCATGAGTGATTCC
AACTATGTTGTCAGGGGCAATGCCCGTCTGCCTGTAAAATGGATGGCCCCCGAAAGCCTG
TTTGAAGGCATCTACACCATTAAGAGTGATGTCTGGTCATATGGAATATTACTGTGGGAA
ATCTTCTCACTTGGTGTGAATCCTTACCCTGGCATTCCGGTTGATGCTAACTTCTACAAA
CTGATTCAAAATGGATTTAAAATGGATCAGCCATTTTATGCTACAGAAGAAATATACATT
ATAATGCAATCCTGCTGGGCTTTTGACTCAAGGAAACGGCCATCCTTCCCTAATTTGACT
TCGTTTTTAGGATGTCAGCTGGCAGATGCAGAAGAAGCGATGTATCAGAATGTGGATGGC
CGTGTTTCGGAATGTCCTCACACCTACCAAAACAGGCGACCTTTCAGCAGAGAGATGGAT
TTGGGGCTACTCTCTCCGCAGGCTCAGGTCGAAGATTCGTAG</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>993</residue_number>
    <molecular_weight>112902.5</molecular_weight>
    <theoretical_pi>5.43</theoretical_pi>
    <pfams>
      <pfam>
        <name>ig</name>
        <pfam_id>PF00047</pfam_id>
      </pfam>
      <pfam>
        <name>Pkinase_Tyr</name>
        <pfam_id>PF07714</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>544-563</region>
    </transmembrane_regions>
    <signal_regions>
      <region>1-26</region>
    </signal_regions>
    <protein_sequence>&gt;FL cytokine receptor
MPALARDGGQLPLLVVFSAMIFGTITNQDLPVIKCVLINHKNNDSSVGKSSSYPMVSESP
EDLGCALRPQSSGTVYEAAAVEVDVSASITLQVLVDAPGNISCLWVFKHSSLNCQPHFDL
QNRGVVSMVILKMTETQAGEYLLFIQSEATNYTILFTVSIRNTLLYTLRRPYFRKMENQD
ALVCISESVPEPIVEWVLCDSQGESCKEESPAVVKKEEKVLHELFGTDIRCCARNELGRE
CTRLFTIDLNQTPQTTLPQLFLKVGEPLWIRCKAVHVNHGFGLTWELENKALEEGNYFEM
STYSTNRTMIRILFAFVSSVARNDTGYYTCSSSKHPSQSALVTIVEKGFINATNSSEDYE
IDQYEEFCFSVRFKAYPQIRCTWTFSRKSFPCEQKGLDNGYSISKFCNHKHQPGEYIFHA
ENDDAQFTKMFTLNIRRKPQVLAEASASQASCFSDGYPLPSWTWKKCSDKSPNCTEEITE
GVWNRKANRKVFGQWVSSSTLNMSEAIKGFLVKCCAYNSLGTSCETILLNSPGPFPFIQD
NISFYATIGVCLLFIVVLTLLICHKYKKQFRYESQLQMVQVTGSSDNEYFYVDFREYEYD
LKWEFPRENLEFGKVLGSGAFGKVMNATAYGISKTGVSIQVAVKMLKEKADSSEREALMS
ELKMMTQLGSHENIVNLLGACTLSGPIYLIFEYCCYGDLLNYLRSKREKFHRTWTEIFKE
HNFSFYPTFQSHPNSSMPGSREVQIHPDSDQISGLHGNSFHSEDEIEYENQKRLEEEEDL
NVLTFEDLLCFAYQVAKGMEFLEFKSCVHRDLAARNVLVTHGKVVKICDFGLARDIMSDS
NYVVRGNARLPVKWMAPESLFEGIYTIKSDVWSYGILLWEIFSLGVNPYPGIPVDANFYK
LIQNGFKMDQPFYATEEIYIIMQSCWAFDSRKRPSFPNLTSFLGCQLADAEEAMYQNVDG
RVSECPHTYQNRRPFSREMDLGLLSPQAQVEDS</protein_sequence>
  </protein_properties>
  <genbank_protein_id>116497195</genbank_protein_id>
  <uniprot_id>P36888</uniprot_id>
  <uniprot_name>FLT3_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>BC126350</genbank_gene_id>
  <genecard_id>FLT3</genecard_id>
  <geneatlas_id>FLT3</geneatlas_id>
  <hgnc_id>HGNC:3765</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Small D, Levenstein M, Kim E, Carow C, Amin S, Rockwell P, Witte L, Burrow C, Ratajczak MZ, Gewirtz AM, et al.: STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):459-63.</reference_text>
      <pubmed_id>7507245</pubmed_id>
    </reference>
    <reference>
      <reference_text>Rosnet O, Schiff C, Pebusque MJ, Marchetto S, Tonnelle C, Toiron Y, Birg F, Birnbaum D: Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells.  Blood. 1993 Aug 15;82(4):1110-9.</reference_text>
      <pubmed_id>8394751</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Rosnet O, Mattei MG, Marchetto S, Birnbaum D: Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene. Genomics. 1991 Feb;9(2):380-5.</reference_text>
      <pubmed_id>2004790</pubmed_id>
    </reference>
    <reference>
      <reference_text>Oppermann FS, Gnad F, Olsen JV, Hornberger R, Greff Z, Keri G, Mann M, Daub H: Large-scale proteomics analysis of the human kinome.  Mol Cell Proteomics. 2009 Jul;8(7):1751-64. Epub 2009 Apr 15.</reference_text>
      <pubmed_id>19369195</pubmed_id>
    </reference>
    <reference>
      <reference_text>Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S, O'Meara S, Vastrik I, Schmidt EE, Avis T, Barthorpe S, Bhamra G, Buck G, Choudhury B, Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Menzies A, Mironenko T, Perry J, Raine K, Richardson D, Shepherd R, Small A, Tofts C, Varian J, Webb T, West S, Widaa S, Yates A, Cahill DP, Louis DN, Goldstraw P, Nicholson AG, Brasseur F, Looijenga L, Weber BL, Chiew YE, DeFazio A, Greaves MF, Green AR, Campbell P, Birney E, Easton DF, Chenevix-Trench G, Tan MH, Khoo SK, Teh BT, Yuen ST, Leung SY, Wooster R, Futreal PA, Stratton MR: Patterns of somatic mutation in human cancer genomes.  Nature. 2007 Mar 8;446(7132):153-8.</reference_text>
      <pubmed_id>17344846</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K, Dooling D, Dunford-Shore BH, McGrath S, Hickenbotham M, Cook L, Abbott R, Larson DE, Koboldt DC, Pohl C, Smith S, Hawkins A, Abbott S, Locke D, Hillier LW, Miner T, Fulton L, Magrini V, Wylie T, Glasscock J, Conyers J, Sander N, Shi X, Osborne JR, Minx P, Gordon D, Chinwalla A, Zhao Y, Ries RE, Payton JE, Westervelt P, Tomasson MH, Watson M, Baty J, Ivanovich J, Heath S, Shannon WD, Nagarajan R, Walter MJ, Link DC, Graubert TA, DiPersio JF, Wilson RK: DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome.  Nature. 2008 Nov 6;456(7218):66-72.</reference_text>
      <pubmed_id>18987736</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Sorafenib</name>
        <accession>HMDB14542</accession>
      </metabolite>
      <reference>
        <reference_text>Auclair D, Miller D, Yatsula V, Pickett W, Carter C, Chang Y, Zhang X, Wilkie D, Burd A, Shi H, Rocks S, Gedrich R, Abriola L, Vasavada H, Lynch M, Dumas J, Trail PA, Wilhelm SM: Antitumor activity of sorafenib in FLT3-driven leukemic cells.  Leukemia. 2007 Mar;21(3):439-45. Epub 2007 Jan 4.</reference_text>
        <pubmed_id>17205056</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sorafenib</name>
        <accession>HMDB14542</accession>
      </metabolite>
      <reference>
        <reference_text>Lierman E, Lahortiga I, Van Miegroet H, Mentens N, Marynen P, Cools J: The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors. Haematologica. 2007 Jan;92(1):27-34.</reference_text>
        <pubmed_id>17229632</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sunitinib</name>
        <accession>HMDB15397</accession>
      </metabolite>
      <reference>
        <reference_text>O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003 May 1;101(9):3597-605. Epub 2003 Jan 16.</reference_text>
        <pubmed_id>12531805</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sunitinib</name>
        <accession>HMDB15397</accession>
      </metabolite>
      <reference>
        <reference_text>O'Farrell AM, Foran JM, Fiedler W, Serve H, Paquette RL, Cooper MA, Yuen HA, Louie SG, Kim H, Nicholas S, Heinrich MC, Berdel WE, Bello C, Jacobs M, Scigalla P, Manning WC, Kelsey S, Cherrington JM: An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res. 2003 Nov 15;9(15):5465-76.</reference_text>
        <pubmed_id>14654525</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sunitinib</name>
        <accession>HMDB15397</accession>
      </metabolite>
      <reference>
        <reference_text>Baratte S, Sarati S, Frigerio E, James CA, Ye C, Zhang Q: Quantitation of SU1 1248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction. J Chromatogr A. 2004 Jan 23;1024(1-2):87-94.</reference_text>
        <pubmed_id>14753710</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sunitinib</name>
        <accession>HMDB15397</accession>
      </metabolite>
      <reference>
        <reference_text>Schmidt-Arras D, Schwable J, Bohmer FD, Serve H: Flt3 receptor tyrosine kinase as a drug target in leukemia.  Curr Pharm Des. 2004;10(16):1867-83.</reference_text>
        <pubmed_id>15180525</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sunitinib</name>
        <accession>HMDB15397</accession>
      </metabolite>
      <reference>
        <reference_text>Yee KW, Schittenhelm M, O'Farrell AM, Town AR, McGreevey L, Bainbridge T, Cherrington JM, Heinrich MC: Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. Blood. 2004 Dec 15;104(13):4202-9. Epub 2004 Aug 10.</reference_text>
        <pubmed_id>15304385</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sunitinib</name>
        <accession>HMDB15397</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
